Acute graft-versus-host disease (GVHD) is the most important complication of allogeneic bone marrow transplantation. We investigated the possibility of predicting severe acute GVHD using plasma interleukin-10 levels in 31 patients who underwent allogeneic bone marrow transplantation. In patients with acute GVHD, the interleukin-10 (IL-10) level increased significantly from the aplastic phase through the leukocyte recovery phase after transplantation (P Ͻ 0.05, paired t-test). The ratio of the IL-10 level in the aplastic phase to that in the leukocyte recovery phase was significantly correlated with the severity of acute GVHD (P Ͻ 0.05, t-test), and the incidence of grade III or IV disease was significantly increased (P Ͻ 0.0001). Since IL-10 antagonizes various other cytokines that induce acute GVHD, determination of the IL-10 level is equivalent to assessing the total production of cytokines promoting GVHD. The ratio of the IL-10 level in the aplastic phase to that in the recovery phase seems to be useful for predicting the subsequent risk of acute GVHD.
At present, bone marrow transplantation (BMT) is the most common treatment for hematologic malignancies and severe immunodeficiency. Since graft-versus-host disease (GVHD) is the most serious and most frequent complication of BMT, control of GVHD is vitally important. Many reports have already appeared on the mechanism of onset of GVHD, 1,2 but there have been few investigations on the effects of interleukin (IL)-10. IL-10 inhibits the actions of inflammatory cytokines, such as IFN-␥, IL-1, IL-6 and TNF-␣, which are believed to stimulate acute GVHD. 3, 4 The plasma IL-10 concentration may reflect its overall secretion in response to various inflammatory cytokines, suggesting that there may be a close association between the IL-10 concentration and acute GVHD.
In the present study, we examined the possibility of pre- dicting the severity of GVHD by monitoring IL-10 levels from the aplastic phase through the leukocyte recovery phase in 31 patients who underwent allogeneic BMT over the past 3 years.
Materials and methods
The subjects were 31 patients who underwent allogeneic BMT at our institution from October 1995 to September 1998. Table 1 shows the age, gender, underlying disease, and disease stage of the subjects, as well as the conditioning regimen and GVHD prophylaxis. The conditioning regimen was Bu + CY + TBI (Bu at a dose of 4 mg/kg/day × 2 days, CY at 30 mg/kg/day × 2 days, and TBI at 3 Gy × 4), or Bu + CY (Bu at 4 mg/kg/day × 4 days and CY at 60 mg/kg/day × 2 days). For GVHD prophylaxis, the basic treatment was CsA plus methotrexate plus methylprednisolone 5 or CsA plus methotrexate. CsA was infused from day −1 for 24 h, and was kept at a target blood level of 400 to 600 ng/ml until marrow engraftment, after which the dosage was varied depending on the symptoms of GVHD. If GVHD became worse, the doses of CsA and methylprednisolone were increased or CsA was replaced with FK506. Granulocyte colony-stimulating factor was administered to all patients from day 5 until the white blood cell count exceeded 10 × 10 9 /l. The classification of GVHD was based on the Seattle diagnostic criteria, and the highest grade until day 100 after transplantation was determined. The plasma IL-10 level was measured in duplicate at the time of the lowest leukocyte count after BMT (aplastic phase) and at the time of the most rapid recovery of the leukocyte count (recovery phase), and the mean values were determined.
Blood samples were collected in tubes containing 3.8% citric acid at a 1:9 ratio. After separation by centrifugation at 1500 g for 10 min at 4°C, plasma was stored at −80°C. The plasma IL-10 level was measured using an ELISA kit from Endogen (Woburn, MA, USA). The sensitivity of this kit was Ͻ3 pg/ml. Statistical analysis was done using the paired t-test or t-test as appropriate, and P Ͻ 0.05 was considered to indicate a significant difference.
Results
Among the 31 patients, six developed severe GVHD of grade III or IV, five had grade II disease, seven had grade AML = acute myelogenous leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myelogenous leukemia; MDS = myelodysplastic syndrome; RA = refractory anemia; RAEB = refractory anemia with excess of blasts; SAA = severe aplastic anemia; CR = complete remission; CP = chronic phase; AP = accelerated phase; NR = no remission; BU = busulfan; CY = cyclophosphamide; TBI = total body irradiation; TLI = total lymphoid irradiation; CsA = cyclosporin, MTX = methotrexate, mPSL = methylprednisolone. 1-24) for the patients without GVHD. The patients with GVHD showed significant elevation of the plasma IL-10 level in the recovery phase after BMT when compared to the patients without GVHD (P Ͻ 0.05 by the paired t-test) (Figure 1) . The relationship between the grade of GVHD and the ratio of the increase of IL-10 from the aplastic phase to the leukocyte recovery phase (IL-10 ratio) was assessed in all 31 patients. Significant differences were observed between GVHD of grade 0 vs I, grade I vs II (P Ͻ 0.05), and grade II vs grade III or IV (P Ͻ 0.0001). The IL-10 ratio was significantly higher in patients with severe GVHD (grades III or IV) than in the other patients (P Ͻ 0.0001) (Figure 2 ).
Blood samples were withdrawn twice during the aplastic phase and on the day when the white blood cell count was recovering most rapidly. Because blood collection was performed rather early after BMT while acute GVHD had not yet developed or was still mild, the dose of CsA or methylprednisolone had not been increased in any patient at that time, nor was either drug replaced by FK506 in any patient.
Discussion
IL-10 is a Th2 cytokine which inhibits cytokine production by Th1 cells. IL-10 is reported to block the production of cytokines, particularly interferon-␥, by Th1 cells in the presence of monocytes and macrophages. 3, 6 IL-10 also inhibits the production of monokines (IL-1, IL-6 and tumor necrosis factor-␣) in response to lipopolysaccharide and other stimuli. 4, 7 These properties of IL-10 have led to its use for the treatment of GVHD in several studies, since IL-10 inhibits the activity of antigen-presenting cells and reduces the proliferation of lymphocytes as well as antagonizing lipopolysaccharide, which is involved in the production of inflammatory cytokines. 8, 9 However, treatment with IL-10 did not effectively suppress GVHD in these studies and actually aggravated it in some cases, resulting in a poor prognosis because treatment with this cytokine caused rejection. 10, 11 We interpreted the results obtained in the present study as follows. The production of cytokines by macrophages is one of the earliest immunological responses to BMT. 12 Because their production is stimulated by TBI, chemotherapy, conditioning, and infection in the aplastic phase, the first peak of cytokine production after BMT occurs at the time when transplanted cells are engrafted. The cytokines produced by macrophages are inflammatory cytokines such as IFN-␥, IL-1, IL-6 and TNF-␣, which are closely involved in the development of acute GVHD. 1, 2 In contrast, IL-10 has the potential to inactivate macrophages. It is produced by activated monocytes and is released in response to the production of various inflammatory cytokines (such as IFN-␥, IL-1, IL-6 and TNF-␣), which it inhibits. 4 As a result, the activation of macrophages is also suppressed. In other words, the plasma IL-10 concentration is correlated with the activation of macrophages and with the production by macrophages of inflammatory cytokines such as IFN-␥, IL-1, IL-6 and TNF-␣. Because the production of these other cytokines is correlated with the grade of acute GVHD, the IL-10 concentration may also be correlated with the grade of acute GVHD. At the time when the plasma IL-10 concentration was determined in this study, acute GVHD had not yet developed or was still mild. We found that the IL-10 level could be used to predict the grade of acute GVHD which developed subsequently. In cases where GVHD becomes severe, such predictions may be particularly valuable.
In summary, we found an association between marked elevation of IL-10 in the recovery phase after BMT and severe acute GVHD (grade III or IV). This suggests that IL-10 was released in an attempt to suppress the various inflammatory cytokines that increase during the leukocyte recovery phase. Our findings also suggest that the ratio of the increase in IL-10 from the aplastic to the recovery phase is useful for predicting the subsequent risk of acute GVHD.
